Article

Study results of DME treatment positive

Ampio Pharmaceuticals Inc. has announced the interim results from its ongoing 450 patient, dose finding, 505 (b) 2 study of Optina as a treatment for diabetic macular edema (DME).

 

Greenwood Village, CO-Ampio Pharmaceuticals Inc. has announced the interim results from its ongoing 450 patient, dose finding, 505 (b) 2 study of Optina as a treatment for diabetic macular edema (DME).

The interim analysis was conducted by an independent data review committee (IDRC) comprised of a statistician and an ophthalmologist/retinologist, who were permitted to view the unmasked data from the trial.

At least 30% of patients enrolled in the trial had reached the first 4-week time point and their clinical results were considered representative data for the trial.

“After thorough review of the interim data from the ongoing study, it was determined that there was a treatment dosage that was demonstrating a potentially beneficial anatomic effect,” noted Vaughan Clift, MD, chief regulatory officer for Ampio. “Given that there were no significant safety concerns identified in the study to date, a recommendation to continue the trial was made.”

The IDRC’s recommendation, Dr. Clift said, will allow for the continuation and completion of the trial and initiate an open label extension study using the found dose of the drug.

 

For more articles in this issue of Ophthalmology Times eReport, click here.


 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.